fashion -WSS

fashion

author：entertainment 2025-09-29 19:59:02 - browse：9143

Monica Bertagnolli -- Health Policy coverage from STAT — Dr. Monica Bertagnolli speaks during a visit from first lady Jill Biden to the University of California San Francisco Helen Diller Family Comprehensive Cancer Center in San Francisco, Friday, Oct. 7, 2022. (AP Photo/Jeff Chiu, Pool) Jeff Chiu/AP

WASHINGTON — Sen. Bernie Sanders (I-Vt.) will hold a confirmation hearing next month for Monica Bertagnolli, President Biden’s nominee to run the National Institutes of Health, he said Friday.

Sanders, whose health committee oversees the confirmation of the NIH nominee, had refused to hold a hearing on Bertagnolli until the Biden administration promised more drug pricing reform.

Newsletters

Sign up for D.C. Diagnosis

An insider's guide to the politics and policies of health care.

Please enter a valid email address. Privacy Policy

HHS announced Friday a deal with Regeneron on the development of the Covid-19 monoclonal antibody. That deal seems to have satisfied Sanders’ demands, though Sanders said the administration must add reasonable pricing provisions to all drugs developed with the help of government funding.

“I welcome the Biden Administration’s announcement today that if Regeneron, through a $326 million contract recently signed with HHS, successfully develops a next generation monoclonal antibody for Covid-19 prevention, the list price of this drug must be equal to or lower than the price in other major countries,” Sanders said in a release.

Sen. Elizabeth Warren (D-Mass.) also had withheld support for Bertagnolli’s nomination until Bertagnolli agreed to Warren’s ethics demands. Bertagnolli agreed to not join the pharmaceutical industry or accept payment from the drug industry, until at least four years after leaving her government position.

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： Commercial surrogacy can be ethical, despite pope’s claims

entertainment

leisure time

WSS

Why depression after traumatic brain injury is distinct

The lessons of Aduhelm, an Alzheimer's drug that was not to be

Cognito secures funding to test medical device for Alzheimer's

Vertigo drug brings hope for rare neuron disorder, Niemann

Readout Newsletter: Vertex, Biogen's Aduhelm, and Bristol updates

Cybersecurity threat forces Lurie Children's to take systems offline

focus

fashion

Sign up for D.C. Diagnosis

Wikipedia

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Readout LOUD podcast: ALS dilemma, first MASH drug, and more

What does generative AI mean for health care? We asked experts

Readout Newsletter: Bristol, Sangamo, Gilead, and more

United colonoscopy coverage change 'may cost lives,' doctors say

Ebola: Gilead Sciences antiviral shows promise as new treatment

Hollywood unions extend contract negotiations for actors

Readout Newsletter: CAR

State Dept. review finds Biden bears some blame for Afghanistan failures

WuXi out of biotech trade group, U.S. and China relations to blame

knowledge

Cognito secures funding to test medical device for Alzheimer's

ARCH Venture Partners is raising $3 billion for a life sciences fund

Cognito secures funding to test medical device for Alzheimer's

Cognito secures funding to test medical device for Alzheimer's

HHS secretary Becerra pressed on Change HealthCare cyberattack

Readout Newsletter: Bristol, Sangamo, Gilead, and more

entertainment

entertainment

leisure time

explore